PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Completed · Phase 1 · NCT04887194
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $110,598
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- Mirati Therapeutics Inc.
- Tested
- Sitravatinib (drug), Warfarin (drug), Dextromethorphan (drug), Midazolam (drug), Digoxin (drug), Rosuvastatin (drug), Nivolumab (drug)
- Dates
- Started 2021-04-08; completion 2022-12-22
- Results posted
- Not yet
Study 516-010 is an open-label Phase 1, drug-drug interaction and QTc study evaluating the effect of sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.
From ClinicalTrials.gov, last updated 2024-05-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mirati Therapeutics, Inc. reported $110,598 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Next Oncology $110,598
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.